Sept 2 (Reuters) - Novo Nordisk said the

shortage of lower strengths of its diabetes drug Ozempic has

deteriorated, with intermittent shortages for all strengths

expected into the final quarter of 2024 due to increased demand

and along with capacity constraints at some of its manufacturing

sites.

In a note published by the European Medicines Agency (EMA)

on Monday, the obesity drug maker recommended healthcare workers

continue limiting treatment initiation of new patients on

Ozempic and its other diabetic drug, Victoza, until the supply

situation improves.